Leadingtac Pharmaceutical  Co., Ltd. Was founded in 2019 and is a preclinical-stage company focused on the development of First-in-class/Best-in-class small molecule innovative drugs. Located in the Zhangjiang Science City in Shanghai, China, Leadtac is committed to expand the targeted protein degradation (TPD) drug technologies to provide transformative solutions for patients in two therapeutic areas with unmet medical needs: autoimmunity and oncology.

The company founder studied at leading U.S. universities and worked as executives at leading multinational pharmaceutical companies and CROs, advancing several small molecule drugs to the clinical trial stage, with years of accumulated knowledge and rich practical experience in the field of small molecule innovative drug development, especially protein degradation. Based on our R&D experience and differentiation strategy, our R&D team has established Nano-SPUD®, a target protein ubiquitination and degradation platform for the rapid screening and development of target intracellular proteins and E3 ligases, and Lyso-SPUD®, a target protein ubiquitination and degradation platform for the screening and development of target extracellular proteins. The Company's first pipeline based on its own Nano-SPUD® platform was formally approved by the U.S. FDA in May 2023 and by the Chinese NMPA in October 2023, and the clinical Phase 1 study was successfully conducted in China in June 2024, completing the administration of the first dose to healthy subjects. The  pipeline has global intellectual property rights. The second pipeline (First-in-class) of preclinical candidates (PCCs) has been successfully selected and progressed well in in vitro and ex vivo efficacy models.

As an innovation-driven biopharmaceutical company, Leadtac is committed to the mission of "Pioneering protein degrader technology, transforming patient life" , and is deeply engaged in the discovery and development of targeted protein degradation drugs.